![Jason Robins](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason Robins
Director Financiero/CFO en
OCULAR THERAPEUTIX, INC.
.
Perfil
Mr. Jason S.
Robins is a Chief Financial & Accounting Officer at Ocular Therapeutix, Inc. Mr. Robins was previously employed as a Vice President-Finance by Fusion Pharmaceuticals, Inc. He received his undergraduate degree from Babson College, a graduate degree from Harvard Mit Health Sciences & Technology and an MBA from MIT Sloan School of Management.
Cargos activos de Jason Robins
| Empresas | Cargo | Inicio |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Director Financiero/CFO | 20/01/2026 |
Antiguos cargos conocidos de Jason Robins.
| Empresas | Cargo | Fin |
|---|---|---|
| FUSN PHAR | Director Financiero/CFO | 01/12/2024 |
Formación de Jason Robins.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
49
Relaciones de 1er grado
5
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Ocular Therapeutix, Inc.
 Ocular Therapeutix, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for retinal diseases & conditions of the eye | Health Technology |
Babson College
 Babson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Mit Health Sciences & Technology
 Harvard Mit Health Sciences & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
- Bolsa de valores
- Insiders
- Jason Robins
